title: Intravenous C-type natriuretic peptide augments behavioral and endocrine effects of cholecystokinin tetrapeptide in healthy men.
abstract: Given the anxiogenic effects of the type-B natriuretic peptide receptor agonist C-type natriuretic peptide (CNP) in rodents, we investigated the influence of CNP pretreatment upon the behavioral and endocrine action of the panicogen cholecystokinin tetrapeptide (CCK-4) in healthy men. In a randomized double-blind balanced design, 20 male volunteers were given an intravenous infusion of 300 microg of CNP vs. placebo followed by 25 microg of CCK-4. The behavior was assessed using panic, anxiety, and dissociation questionaires before the infusion and after the CCK-4 stimulus. Furthermore, the stress-sensitive hormones adrenocorticotropic hormone (ACTH), cortisol, and prolactin were measured. CNP pretreatment enhanced the anxiogenic and prodissociative effects of CCK-4 and significantly augmented the ACTH surge after CCK-4. However, no effect of CNP was seen upon panic symptoms. Our preliminary data support a role of type-B natriuretic peptide receptors in anxiety modulation in normal man.
authors.affiliation: University Hospital Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy, Martinistrasse 52, 20246 Hamburg, Germany. kellner@uke.uni-hamburg.de
authors.forename: M
authors.initials: M
authors.lastname: Kellner
authors.forename: A
authors.initials: A
authors.lastname: Yassouridis
authors.forename: Y
authors.initials: Y
authors.lastname: Hua
authors.forename: M
authors.initials: M
authors.lastname: Wendrich
authors.forename: H
authors.initials: H
authors.lastname: Jahn
authors.forename: K
authors.initials: K
authors.lastname: Wiedemann
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000187:drug effects; D000328:Adult; D001007:Anxiety / Q000139:chemically induced / Q000523:psychology; D001526:Behavioral Symptoms / Q000188:drug therapy / Q000523:psychology; D004311:Double-Blind Method; D004702:Endocrine Glands / Q000187:drug effects*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D020098:Natriuretic Peptide, C-Type / Q000008:administration & dosage* / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D012016:Reference Values; D013758:Tetragastrin / Q000627:therapeutic use*
chemical_list: D005765:Gastrointestinal Agents; D013758:Tetragastrin; D020098:Natriuretic Peptide, C-Type; D000324:Adrenocorticotropic Hormone